Genomic and molecular profiling predicts response to temozolomide in melanoma.
about
Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cellsA New Epigenetic Mechanism of Temozolomide Action in Glioma CellsProteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.Mycobacterium bovis-BCG vaccination induces specific pulmonary transcriptome biosignatures in mice.Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.Predictive biomarker validation in practice: lessons from real trials.Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies.Patterns of expression of DNA repair genes and relapse from melanoma.Oncolytic polio virotherapy of cancerCell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trial.Adenovirus-mediated FKHRL1/TM sensitizes melanoma cells to apoptosis induced by temozolomide.Chemotherapy induced microsatellite instability and loss of heterozygosity in chromosomes 2, 5, 10, and 17 in solid tumor patients.A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.Design of clinical trials for biomarker research in oncology.An optimized workflow for improved gene expression profiling for formalin-fixed, paraffin-embedded tumor samples.Genomic advances and their impact on clinical trial designRelationship between humoral response against hepatitis C virus and disease overcome.Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.Optimizing regional infusion treatment strategies for melanoma of the extremitiesIndependent validation of a model using cell line chemosensitivity to predict response to therapy.Molecular markers of tumor progression in melanoma.DNA methylation as a universal biomarker.Regional treatment strategies for in-transit melanoma metastasis.Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations.Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.Single-cell analysis challenges the connection between autophagy and senescence induced by DNA damage.Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.Immunohistochemical analysis of O(6)-methylguanine-DNA methyltransferase in human melanoma in comparison with skin squamous cell carcinoma.Statistical Contributions to Bioinformatics: Design, Modeling, Structure Learning, and Integration.MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.MGMT assessment in pituitary adenomas: comparison of different immunohistochemistry fixation chemicals.Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients.
P2860
Q54606435-4EA26A58-7C42-4672-9043-72C4832CF4FCQ54831207-3700697C-B16D-4479-8862-74C95447AC86Q54831217-2290E75F-1545-4770-90C6-E76F4489A0E4Q54831220-E81E851F-4A4C-4D51-9F7B-CEBF5F239346Q54831223-AE72E538-0048-4C2E-AD6A-8324DF303F50Q54831225-CA3B0B87-F52A-491B-85FA-52E8B51A147BQ54831226-23E0792C-2E61-4621-B9AE-4E602D452D59Q54831227-7EE77614-305B-47B6-8B8F-CB4A9DC7788EQ54831228-ACF212A1-45AB-4556-8A9F-568BEB7F573EQ54831229-7A8B4051-4C8B-4872-A470-F14F9DFFC82AQ54831230-AE4228D2-81A5-4969-AC05-8771E4514F67Q54831231-66738BC3-B940-4C57-8FA6-EF110D896C3EQ54831238-5A9BF5F2-8F77-43E6-B00E-B809A5706BE0Q54831241-47335066-D1D6-4FF6-A039-F69A1D10B653Q54831242-CE6AD750-8EBD-4D7F-9615-5FD74D38B8B7Q54831244-0D25ECE0-E4D6-4ACF-BE5B-B281530EB262Q54831245-DD6BAFD1-7609-48F9-AD47-E6C94380A3B1Q54831247-B051E3B5-934D-47AD-9BF1-652F3ED06F0FQ54831249-4967FD16-AE3C-4229-B4D1-816CFE0C3EC9Q54831250-E1E60E8E-06D4-47B6-B333-47C7B4A7BB54Q54831251-D6CC80D5-261A-4D99-BAFB-2735F39C59FEQ54831253-3717EAC7-ADED-4991-B56C-515E9DF4A63AQ54831256-1A724DDC-FA37-4BCF-9158-C6AAD62F7A73Q54831259-5D0EA369-7F80-4695-8E6F-CFD89E8A22A2Q54831264-9CA774CD-D038-47CF-8F59-7E2EB5AF245EQ54954013-4CBC8867-B2AB-4BEE-9693-1F547C6729C3
P1343
Q28484515-76C783B6-C375-4BF3-8860-0DB1074D3942Q28547489-3C052366-FD1A-4A4C-BBA7-010CBEC1AF77Q33613608-763ED1C1-4308-4948-9B09-08662A6432D0Q33623697-0AF061C4-3DCA-41B5-9979-CF1CE644DB65Q33914197-68A67888-39A6-41E2-AE54-B2A79EBFB08AQ34042498-A5DC65F2-37A4-43C6-99BA-3D71F3DC312EQ34110168-18859101-AAF7-4971-902F-962D8E374B89Q34205443-C7099FA7-1558-41DA-B9FD-651DE88E93D0Q34273603-04683A9A-9662-42D4-A403-DC16AE747B29Q34425385-A9316764-8E89-4B58-A0C9-87F08D05D94BQ34480023-D23274DE-1FEA-4CD8-944D-44AFAF93EB46Q34488011-FB65318A-8E9A-48D0-A954-8CFA68BFA08AQ34659119-AF69E866-AD4B-4224-8314-62DC20C24E06Q35731493-26028106-5F94-4D87-B5A4-492466BCFDF8Q35789708-CA163AFD-6189-42AE-B737-34B8A89F4546Q36863522-C8DCB55E-16F3-43F9-B3EF-2D375152E1A9Q37279699-E2B93D2A-C567-4B93-88C9-233938789CABQ37558730-FFD7A57F-905E-4FC9-B197-B49518E0E170Q37618946-C53BA14C-C715-4331-894D-6CB965B0A154Q37628698-DCBE4EFF-E0CC-4911-8568-BAB35ED1EE7DQ37640491-5B2C3D85-4A6E-400A-BDA9-D1A6C5957DC6Q37641784-1B8EE881-65C2-41AC-9E6F-C43BFEE26206Q37750858-0C00843A-684B-42A0-B20D-EF4A5603253CQ37812815-ED87AB85-3F8A-4BF4-A4CD-853B8C27E138Q37865580-5C0919E2-F327-4B79-B7F6-05A297046FD0Q38041729-0090B6BE-F8C5-4B4A-A29A-900DB1E9406CQ38225830-83A58A2E-4E5C-4CB6-8103-FF89414AB288Q38903238-F58E4D11-7A18-40AB-8878-2B0E0EA40D56Q38907601-DEE6FD23-1F21-47C9-9172-FA393B720E2DQ39384950-4DB697BB-737D-48C0-9557-332605AD2DD7Q39457448-7E02E023-7401-48D8-9C85-85459628E564Q47110630-49174B5E-1B7D-4200-942A-0C0953423F7FQ47161911-50214DB1-5183-487F-AB98-7A907C10CA65Q49979233-523C70B0-A6DF-4677-8804-81401AAC2F85Q54537693-2E433B17-3C30-4D6D-9607-BDBCCFD8A749
P2860
Genomic and molecular profiling predicts response to temozolomide in melanoma.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Genomic and molecular profiling predicts response to temozolomide in melanoma.
@ast
Genomic and molecular profiling predicts response to temozolomide in melanoma.
@en
Genomic and molecular profiling predicts response to temozolomide in melanoma.
@nl
type
label
Genomic and molecular profiling predicts response to temozolomide in melanoma.
@ast
Genomic and molecular profiling predicts response to temozolomide in melanoma.
@en
Genomic and molecular profiling predicts response to temozolomide in melanoma.
@nl
prefLabel
Genomic and molecular profiling predicts response to temozolomide in melanoma.
@ast
Genomic and molecular profiling predicts response to temozolomide in melanoma.
@en
Genomic and molecular profiling predicts response to temozolomide in melanoma.
@nl
P2093
P4510
P1476
Genomic and molecular profiling predicts response to temozolomide in melanoma.
@en
P2093
Anil Potti
Christina K Augustine
Douglas S Tyler
Francis Ali-Osman
Jin Soo Yoo
Joseph R Nevins
Patricia A Zipfel
Yasunori Yoshimoto
P304
P356
10.1158/1078-0432.CCR-08-1916
P407
P577
2009-01-01T00:00:00Z